174 related articles for article (PubMed ID: 33389908)
61. Accuracy of a commercial multiplex PCR for the diagnosis of bacterial vaginosis.
van der Veer C; van Houdt R; van Dam A; de Vries H; Bruisten S
J Med Microbiol; 2018 Sep; 67(9):1265-1270. PubMed ID: 29985123
[TBL] [Abstract][Full Text] [Related]
62. Fecal Microbiota Transplantation: A Potential Tool for Treatment of Human Female Reproductive Tract Diseases.
Quaranta G; Sanguinetti M; Masucci L
Front Immunol; 2019; 10():2653. PubMed ID: 31827467
[TBL] [Abstract][Full Text] [Related]
63. Gardnerella vaginalis and anaerobic bacteria in the etiology of bacterial (nonspecific) vaginosis.
Spiegel CA; Davick P; Totten PA; Chen KC; Eschenbach DA; Amsel R; Holmes KK
Scand J Infect Dis Suppl; 1983; 40():41-6. PubMed ID: 6607521
[TBL] [Abstract][Full Text] [Related]
64. Bacterial vaginosis in a district genitourinary medicine department: significance of vaginal microbiology and anaerobes.
Saidi SA; Mandal D; Curless E
Int J STD AIDS; 1994; 5(6):405-8. PubMed ID: 7849117
[TBL] [Abstract][Full Text] [Related]
65. Association of asymptomatic bacterial vaginosis with persistence of female genital human papillomavirus infection.
Kero K; Rautava J; Syrjänen K; Grenman S; Syrjänen S
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2215-2219. PubMed ID: 28681204
[TBL] [Abstract][Full Text] [Related]
66. Characterisation and selection of a Lactobacillus species to re-colonise the vagina of women with recurrent bacterial vaginosis.
McLEAN NW; Rosenstein IJ
J Med Microbiol; 2000 Jun; 49(6):543-552. PubMed ID: 10847208
[TBL] [Abstract][Full Text] [Related]
67. Using an in-vitro biofilm model to assess the virulence potential of bacterial vaginosis or non-bacterial vaginosis Gardnerella vaginalis isolates.
Castro J; Alves P; Sousa C; Cereija T; França Â; Jefferson KK; Cerca N
Sci Rep; 2015 Jun; 5():11640. PubMed ID: 26113465
[TBL] [Abstract][Full Text] [Related]
68. Lactobacillus iners: Friend or Foe?
Petrova MI; Reid G; Vaneechoutte M; Lebeer S
Trends Microbiol; 2017 Mar; 25(3):182-191. PubMed ID: 27914761
[TBL] [Abstract][Full Text] [Related]
69. Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection.
Di Paola M; Sani C; Clemente AM; Iossa A; Perissi E; Castronovo G; Tanturli M; Rivero D; Cozzolino F; Cavalieri D; Carozzi F; De Filippo C; Torcia MG
Sci Rep; 2017 Aug; 7(1):10200. PubMed ID: 28860468
[TBL] [Abstract][Full Text] [Related]
70. Role of Gardnerella vaginalis in the pathogenesis of bacterial vaginosis: a conceptual model.
Schwebke JR; Muzny CA; Josey WE
J Infect Dis; 2014 Aug; 210(3):338-43. PubMed ID: 24511102
[TBL] [Abstract][Full Text] [Related]
71. Sexual practices have a significant impact on the vaginal microbiota of women who have sex with women.
Plummer EL; Vodstrcil LA; Fairley CK; Tabrizi SN; Garland SM; Law MG; Hocking JS; Fethers KA; Bulach DM; Murray GL; Bradshaw CS
Sci Rep; 2019 Dec; 9(1):19749. PubMed ID: 31874964
[TBL] [Abstract][Full Text] [Related]
72. Insights into the role of vaginal microbiome in women's health.
Deka N; Hassan S; Seghal Kiran G; Selvin J
J Basic Microbiol; 2021 Dec; 61(12):1071-1084. PubMed ID: 34763361
[TBL] [Abstract][Full Text] [Related]
73. Role of Immunity and Vaginal Microbiome in Clearance and Persistence of Human Papillomavirus Infection.
Ntuli L; Mtshali A; Mzobe G; Liebenberg LJ; Ngcapu S
Front Cell Infect Microbiol; 2022; 12():927131. PubMed ID: 35873158
[TBL] [Abstract][Full Text] [Related]
74. The Microbiome and Gynecologic Cancer: Current Evidence and Future Opportunities.
Chambers LM; Bussies P; Vargas R; Esakov E; Tewari S; Reizes O; Michener C
Curr Oncol Rep; 2021 Jun; 23(8):92. PubMed ID: 34125319
[TBL] [Abstract][Full Text] [Related]
75. The Diversity of Vaginal Microbiota Predicts Neoadjuvant Chemotherapy Responsiveness in Locally Advanced Cervical Cancer.
Wang Z; Xiao R; Huang J; Qin X; Hu D; Guo E; Liu C; Lu F; You L; Sun C; Chen G
Microb Ecol; 2022 Jul; 84(1):302-313. PubMed ID: 34405250
[TBL] [Abstract][Full Text] [Related]
76. Microbes in gynecologic cancers: Causes or consequences and therapeutic potential.
Wahid M; Dar SA; Jawed A; Mandal RK; Akhter N; Khan S; Khan F; Jogaiah S; Rai AK; Rattan R
Semin Cancer Biol; 2022 Nov; 86(Pt 2):1179-1189. PubMed ID: 34302959
[TBL] [Abstract][Full Text] [Related]
77. Gut and genital tract microbiomes: Dysbiosis and link to gynecological disorders.
Elkafas H; Walls M; Al-Hendy A; Ismail N
Front Cell Infect Microbiol; 2022; 12():1059825. PubMed ID: 36590579
[TBL] [Abstract][Full Text] [Related]
78. Unraveling the Dysbiosis of Vaginal Microbiome to Understand Cervical Cancer Disease Etiology-An Explainable AI Approach.
Sekaran K; Varghese RP; Gopikrishnan M; Alsamman AM; El Allali A; Zayed H; Doss C GP
Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107694
[TBL] [Abstract][Full Text] [Related]
79. Dysbiosis of vaginal and cervical microbiome is associated with uterine fibroids.
Mao X; Chen H; Peng X; Zhao X; Yu Z; Xu D
Front Cell Infect Microbiol; 2023; 13():1196823. PubMed ID: 37743857
[TBL] [Abstract][Full Text] [Related]
80. Shifts in gut and vaginal microbiomes are associated with cancer recurrence time in women with ovarian cancer.
Jacobson D; Moore K; Gunderson C; Rowland M; Austin R; Honap TP; Xu J; Warinner C; Sankaranarayanan K; Lewis CM
PeerJ; 2021; 9():e11574. PubMed ID: 34178459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
